CN105924437B - 作为iii型受体酪氨酸激酶抑制剂的化合物 - Google Patents

作为iii型受体酪氨酸激酶抑制剂的化合物 Download PDF

Info

Publication number
CN105924437B
CN105924437B CN201610248287.9A CN201610248287A CN105924437B CN 105924437 B CN105924437 B CN 105924437B CN 201610248287 A CN201610248287 A CN 201610248287A CN 105924437 B CN105924437 B CN 105924437B
Authority
CN
China
Prior art keywords
methyl
base
pyridine
indazole
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610248287.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105924437A (zh
Inventor
M.L.博伊斯
R.K.德莱尔
E.J.希肯
A.L.肯尼迪
D.A.马里斯卡
F.P.玛姆萨特
M.C.芒森
B.纽豪斯
B.拉斯特
J.P.里齐
M.E.罗德里格兹
G.T.托帕洛夫
赵千
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN105924437A publication Critical patent/CN105924437A/zh
Application granted granted Critical
Publication of CN105924437B publication Critical patent/CN105924437B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201610248287.9A 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物 Expired - Fee Related CN105924437B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42254710P 2010-12-13 2010-12-13
US61/422,547 2010-12-13
CN201180067342.XA CN103347882B (zh) 2010-12-13 2011-12-13 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180067342.XA Division CN103347882B (zh) 2010-12-13 2011-12-13 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物

Publications (2)

Publication Number Publication Date
CN105924437A CN105924437A (zh) 2016-09-07
CN105924437B true CN105924437B (zh) 2018-11-30

Family

ID=45478484

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201180067342.XA Expired - Fee Related CN103347882B (zh) 2010-12-13 2011-12-13 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物
CN201610248287.9A Expired - Fee Related CN105924437B (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物
CN201811311712.XA Pending CN109608449A (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201180067342.XA Expired - Fee Related CN103347882B (zh) 2010-12-13 2011-12-13 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811311712.XA Pending CN109608449A (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物

Country Status (32)

Country Link
US (3) US9174981B2 (enExample)
EP (1) EP2651939B1 (enExample)
JP (3) JP5868996B2 (enExample)
KR (1) KR101974665B1 (enExample)
CN (3) CN103347882B (enExample)
AU (3) AU2011344001B2 (enExample)
BR (1) BR112013014854B1 (enExample)
CA (2) CA3027814A1 (enExample)
CL (1) CL2013001712A1 (enExample)
CO (1) CO6751248A2 (enExample)
CR (1) CR20130349A (enExample)
DK (1) DK2651939T3 (enExample)
ES (1) ES2540996T3 (enExample)
HR (1) HRP20150571T1 (enExample)
HU (1) HUE025416T2 (enExample)
IL (1) IL226911A (enExample)
ME (1) ME02172B (enExample)
MX (1) MX2013006763A (enExample)
MY (1) MY172110A (enExample)
NZ (1) NZ613235A (enExample)
PH (1) PH12013501221A1 (enExample)
PL (1) PL2651939T3 (enExample)
PT (1) PT2651939E (enExample)
RS (1) RS54070B1 (enExample)
RU (1) RU2591195C2 (enExample)
SG (1) SG191129A1 (enExample)
SI (1) SI2651939T1 (enExample)
SM (1) SMT201500165B (enExample)
TW (1) TWI527813B (enExample)
UA (1) UA112425C2 (enExample)
UY (1) UY33801A (enExample)
WO (1) WO2012082689A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608449A (zh) * 2010-12-13 2019-04-12 阵列生物制药公司 作为iii型受体酪氨酸激酶抑制剂的化合物

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181861A1 (en) * 2009-12-21 2012-07-30 Array Biopharma Inc Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CN104974078A (zh) * 2015-06-25 2015-10-14 黄荣辉 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
AU2016305513A1 (en) 2015-08-11 2018-03-08 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
JP6912039B2 (ja) 2015-08-12 2021-07-28 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
US10889564B2 (en) 2015-11-02 2021-01-12 Genase Therapeutics B.V. Tetrahydroindazoles and medical uses thereof
CN105198799A (zh) * 2015-11-03 2015-12-30 江苏梦得电镀化学品有限公司 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
PT3468972T (pt) * 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
WO2018019291A1 (en) * 2016-07-29 2018-02-01 The Hong Kong University Of Science And Technology C(sp3)-c(sp2) cross-coupling reaction of organozinc reagents and heterocyclic (pseudo)halides
CN110139852A (zh) 2016-11-04 2019-08-16 奥克兰联合服务有限公司 三环杂环衍生物及其用途
JP6346368B1 (ja) * 2016-11-28 2018-06-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 インダゾール誘導体の塩及びその結晶
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
CN111315742B (zh) 2017-07-28 2023-09-01 株式会社柳韩洋行 制备氨基嘧啶衍生物的方法
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
TWI759829B (zh) 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
WO2025146196A1 (zh) * 2024-01-04 2025-07-10 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822170A (zh) * 2009-12-21 2012-12-12 阵列生物制药公司 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
CN101679409B (zh) * 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
HRP20130660T1 (en) * 2007-04-03 2013-08-31 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
FR2925901B1 (fr) 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
UA112425C2 (uk) 2010-12-13 2016-09-12 Еррей Біофарма Інк. ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822170A (zh) * 2009-12-21 2012-12-12 阵列生物制药公司 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608449A (zh) * 2010-12-13 2019-04-12 阵列生物制药公司 作为iii型受体酪氨酸激酶抑制剂的化合物

Also Published As

Publication number Publication date
UY33801A (es) 2013-06-28
CA3027814A1 (en) 2012-06-21
SI2651939T1 (sl) 2015-07-31
AU2016222468B2 (en) 2017-12-21
HUE025416T2 (en) 2016-02-29
CL2013001712A1 (es) 2013-12-06
CN105924437A (zh) 2016-09-07
CR20130349A (es) 2013-08-09
AU2011344001B2 (en) 2016-06-30
HK1190709A1 (en) 2014-07-11
HRP20150571T1 (xx) 2015-07-03
ME02172B (me) 2015-10-20
PL2651939T3 (pl) 2015-10-30
RU2591195C2 (ru) 2016-07-10
EP2651939A1 (en) 2013-10-23
JP2016040303A (ja) 2016-03-24
JP2018065835A (ja) 2018-04-26
TWI527813B (zh) 2016-04-01
US10669269B2 (en) 2020-06-02
KR20140014109A (ko) 2014-02-05
SMT201500165B (it) 2015-09-07
AU2016222468A1 (en) 2016-09-22
US9809590B2 (en) 2017-11-07
JP2013545808A (ja) 2013-12-26
BR112013014854A2 (pt) 2016-10-18
AU2018201903B2 (en) 2019-09-19
IL226911A (en) 2016-09-29
US20180086758A1 (en) 2018-03-29
US20130274244A1 (en) 2013-10-17
CA2821712C (en) 2019-02-12
PH12013501221A1 (en) 2022-03-30
US20160002232A1 (en) 2016-01-07
JP5868996B2 (ja) 2016-02-24
BR112013014854A8 (pt) 2018-03-27
UA112425C2 (uk) 2016-09-12
PT2651939E (pt) 2015-08-04
RS54070B1 (sr) 2015-10-30
SG191129A1 (en) 2013-07-31
MX2013006763A (es) 2014-01-08
CN109608449A (zh) 2019-04-12
CN103347882A (zh) 2013-10-09
MY172110A (en) 2019-11-14
US9174981B2 (en) 2015-11-03
ES2540996T3 (es) 2015-07-15
CO6751248A2 (es) 2013-09-16
CN103347882B (zh) 2016-05-11
KR101974665B1 (ko) 2019-05-02
BR112013014854B1 (pt) 2020-12-08
CA2821712A1 (en) 2012-06-21
RU2013132758A (ru) 2015-01-20
WO2012082689A1 (en) 2012-06-21
NZ613235A (en) 2015-04-24
EP2651939B1 (en) 2015-04-08
DK2651939T3 (en) 2015-06-01
AU2018201903A1 (en) 2018-04-12
TW201305156A (zh) 2013-02-01

Similar Documents

Publication Publication Date Title
CN105924437B (zh) 作为iii型受体酪氨酸激酶抑制剂的化合物
CN106008523B (zh) 作为TRK激酶抑制剂的被取代的吡唑并[1,5-a]嘧啶化合物
CN105693720B (zh) 作为trk激酶抑制剂的大环化合物
JP7051829B2 (ja) Ｄｎｍｔ１の阻害剤としての置換ピリジン
CN107922390B (zh) Cot调节剂及其使用方法
CN115702025A (zh) 稠合三环kras抑制剂
CN104910148B (zh) 氨基三唑并吡啶和其作为激酶抑制剂的用途
CN105555780B (zh) Syk抑制剂
CN105102453B (zh) 作为布罗莫结构域抑制剂的苯并咪唑酮衍生物
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN105777756B (zh) 杂芳化合物及其在药物中的应用
RS65419B1 (sr) Derivati pirazolila korisni kao sredstva protiv kancera
CN113072551B (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
TWI711611B (zh) Ｃｏｔ調節劑及其使用方法
CN107857755A (zh) 作为trka激酶抑制剂的n‑吡咯烷基、n`‑吡唑基‑脲、硫脲、胍和氰基胍化合物
CN107253963A (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
KR20160025580A (ko) Btk 억제제로서 1급 카복스아미드
CN109311900A (zh) 用于配体依赖性靶蛋白质降解的单官能中间体
CN108715590A (zh) 可用作pim激酶抑制剂的噻唑甲酰胺和吡啶甲酰胺化合物
CN107383009A (zh) 作为fgfr抑制剂的取代的三环化合物
CN105658653A (zh) 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CN116535401A (zh) 新的parp1抑制剂及其应用
WO2021164746A1 (zh) 取代芳基类化合物
TW201927787A (zh) 吡咯並三嗪化合物及抑制ｔａｍ激酶之方法
CN104936958A (zh) 作为γ分泌酶调节剂的新颖的经取代的吡啶并-哌嗪酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1228889

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181130

Termination date: 20211213

CF01 Termination of patent right due to non-payment of annual fee